Structure-Based Design, Synthesis, and In Vivo Antinociceptive Effects of Selective A1 Adenosine Receptor Agonists.
暂无分享,去创建一个
K. Klotz | A. Lavecchia | R. Petrelli | L. Cappellacci | S. Kachler | S. Maione | L. Luongo | F. Del Bello | P. Vita | Mirko Scortichini | S. Boccella | C. Belardo | F. Capone | Fabio Del Bello
[1] E. Novellino,et al. Exploring the Role of N6-Substituents in Potent Dual Acting 5'-C-Ethyltetrazolyladenosine Derivatives: Synthesis, Binding, Functional Assays, and Antinociceptive Effects in Mice ∇. , 2017, Journal of medicinal chemistry.
[2] K. Jacobson,et al. Hypothermia in mouse is caused by adenosine A1 and A3 receptor agonists and AMP via three distinct mechanisms , 2017, Neuropharmacology.
[3] Arthur Christopoulos,et al. Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity , 2017, Cell.
[4] J. Sawynok. Adenosine receptor targets for pain , 2016, Neuroscience.
[5] K. Jacobson,et al. Ocular Purine Receptors as Drug Targets in the Eye. , 2016, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[6] R. Petrelli,et al. Development of C-Methyl Branched Purine Ribonucleoside Analogs: Chemistry, Biological Activity and Therapeutic Potential. , 2016, Current medicinal chemistry.
[7] K. Jacobson,et al. Medicinal chemistry of adenosine, P2Y and P2X receptors , 2016, Neuropharmacology.
[8] K. Jacobson,et al. Identification of A3 adenosine receptor agonists as novel non‐narcotic analgesics , 2016, British journal of pharmacology.
[9] P. Fishman,et al. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis , 2016, Clinical Rheumatology.
[10] Rebecca K Donegan,et al. Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions. , 2016, Journal of medicinal chemistry.
[11] M. Malcangio,et al. Chronic Pain: New Insights in Molecular and Cellular Mechanisms , 2015, BioMed research international.
[12] Riccardo Petrelli,et al. 5'-C-Ethyl-tetrazolyl-N(6)-substituted adenosine and 2-chloro-adenosine derivatives as highly potent dual acting A1 adenosine receptor agonists and A3 adenosine receptor antagonists. , 2015, Journal of medicinal chemistry.
[13] N. Mercuri,et al. Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice , 2014, Experimental Neurology.
[14] A. Usiello,et al. The A1 adenosine receptor as a new player in microglia physiology , 2014, Glia.
[15] Silvia Paoletta,et al. Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. , 2013, Journal of medicinal chemistry.
[16] R. Petrelli,et al. 5'-Chloro-5'-deoxy-(±)-ENBA, a Potent and Selective Adenosine A1 Receptor Agonist, Alleviates Neuropathic Pain in Mice Through Functional Glial and Microglial Changes without Affecting Motor or Cardiovascular Functions , 2012, Molecules.
[17] Kenneth A Jacobson,et al. Controlling murine and rat chronic pain through A3 adenosine receptor activation , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[18] K. Jacobson,et al. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. , 2012, Drug discovery today.
[19] K. Jacobson,et al. Emerging adenosine receptor agonists – an update , 2011, Expert opinion on emerging drugs.
[20] E. Bulger,et al. Increased Neutrophil Adenosine A3 Receptor Expression Is Associated With Hemorrhagic Shock and Injury Severity in Trauma Patients , 2011, Shock.
[21] K. Jacobson,et al. Truncated (N)-Methanocarba Nucleosides as A(1) Adenosine Receptor Agonists and Partial Agonists: Overcoming Lack of a Recognition Element. , 2011, ACS medicinal chemistry letters.
[22] Richard J. Hall,et al. Docking performance of fragments and druglike compounds. , 2011, Journal of medicinal chemistry.
[23] A. Leslie,et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.
[24] Y. Yen,et al. Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents. , 2011, European journal of medicinal chemistry.
[25] R. Stevens,et al. Agonist bound structure of the human adenosine A2a receptor , 2011 .
[26] B. Fredholm,et al. Adenosine induces airway hyperresponsiveness through activation of A3 receptors on mast cells. , 2008, The Journal of allergy and clinical immunology.
[27] L. Jeong,et al. Alternative and improved syntheses of highly potent and selective A3 adenosine receptor agonists, CI-IB-MECA and Thio-CI-IB-MECA , 2007, Archives of pharmacal research.
[28] F. Rossi,et al. The antinociceptive effect of 2-chloro-2′-C-methyl-N6-cyclopentyladenosine (2′-Me-CCPA), a highly selective adenosine A1 receptor agonist, in the rat , 2007, PAIN.
[29] K. Jacobson,et al. Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.
[30] Riccardo Petrelli,et al. Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists. , 2005, Journal of medicinal chemistry.
[31] Richard D. Taylor,et al. Improved protein–ligand docking using GOLD , 2003, Proteins.
[32] J. Richardson,et al. The penultimate rotamer library , 2000, Proteins.
[33] M. Judge,et al. N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects. , 1999, Journal of medicinal chemistry.
[34] C. Martini,et al. 2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. , 1998, Journal of medicinal chemistry.
[35] B. Fredholm,et al. Comparative pharmacology of human adenosine receptor subtypes – characterization of stably transfected receptors in CHO cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[36] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[37] K. Klotz,et al. 2-Chloro-N6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.
[38] R. Egan,et al. Modification of the 5' position of purine nucleosides. 2. Synthesis and some cardiovascular properties of adenosine-5'-(N-substituted)carboxamides. , 1980, Journal of medicinal chemistry.
[39] D. Dubuisson,et al. The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats , 1977, Pain.
[40] CharlesPowell White. NOMENCLATURE AND CLASSIFICATION. , 1901 .
[41] K. Jacobson,et al. Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. , 2015, Brain : a journal of neurology.
[42] G. Cristalli,et al. Photoaffinity Labeling of A 1-adenosine Receptors * , 2011 .
[43] K. Klotz,et al. Adenosine Receptor with Antinociceptive Effects in Mice , 2009 .
[44] K. Klotz,et al. 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 receptor from different species. , 2008, Bioorganic & medicinal chemistry.
[45] E. Elzein,et al. A1 adenosine receptor agonists and their potential therapeutic applications. , 2008, Expert opinion on investigational drugs.
[46] Zhihe Li,et al. Affinity and intrinsic efficacy (IE) of 5'-carbamoyl adenosine analogues for the A1 adenosine receptor--efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF). , 2004, Bioorganic & medicinal chemistry letters.
[47] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .